Summary

The Europe Hepatitis Delta Virus (HDV) infection market is expected to reach USD 31.01 million by 2031 from USD 20.50 million in 2023, growing with a CAGR of 5.5% in the forecast period of 2024 to 2031.
Market Segmentation:
Europe Hepatitis Delta Virus (HDV) Infection Market, By Type (Acute Hepatitis D and Chronic Hepatitis D), Treatment (Surgery (Liver Transplant) and Medication), Drug Type (Branded and Generic), Route of Administration (Oral and Parenteral), Age Group (Adults, Geriatric, and Pediatric), Gender (Female and Male), Transmission (Contaminated Needles, Exposure to Infected Blood, Blood and Plasma Product Transfusion, and Others), End User (Hospitals, Specialty Clinics, Home Care Setting, Research Institutes and Academic Centers, Ambulatory Surgical Centers, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others) Country (Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Denmark, Sweden, Norway, Poland, Austria, Finland, Portugal, Greece, Iceland, Rest of Europe) - Industry Trends and Forecast to 2031

Overview of Europe Hepatitis Delta Virus (HDV) Infection Market Dynamics:

Driver
• Increasing prevalence of hepatitis
Restraint

• High cost of treatment
Opportunity

• Rising innovative drug development
•
Market Players:

The key market players operating in the Europe Hepatitis Delta Virus (HDV) infection market are listed below:

• Gilead Sciences Inc. (U.S.)
• Genentech Inc. (U.S.)
• Alnylam Pharmaceuticals Inc. (U.S.)
• Assembly Biosciences Inc. (U.S.)
• Eiger Pharmaceuticals (U.S.)
• GlobeImmune Inc. (U.S.)
• Huahui Health Ltd. (China)
• Johnson & Johnson Services Inc. (U.S.)
• PharmaEssentia Corporation (Taiwan)
• Replicor (Canada)
• Vir Biotechnology Inc. (U.S.)

ページTOPに戻る

Table of Contents

1 INTRODUCTION 45
1.1 OBJECTIVES OF THE STUDY 45
1.2 MARKET DEFINITION 45
1.3 OVERVIEW OF THE EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET 45
1.4 CURRENCY AND PRICING 47
1.5 LIMITATIONS 47
1.6 MARKETS COVERED 47
2 MARKET SEGMENTATION 50
2.1 MARKETS COVERED 50
2.2 GEOGRAPHICAL SCOPE 51
2.3 YEARS CONSIDERED FOR THE STUDY 52
2.4 DBMR TRIPOD DATA VALIDATION MODEL 53
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 56
2.6 MULTIVARIATE MODELLING 57
2.7 MARKET END USER COVERAGE GRID 58
2.8 DBMR MARKET POSITION GRID 59
2.9 VENDOR SHARE ANALYSIS 60
2.10 SECONDARY SOURCES 61
2.11 ASSUMPTIONS 61
3 EXECUTIVE SUMMARY 62
4 PREMIUM INSIGHTS 66
4.1 PESTAL ANALYSIS 67
4.2 PORTER FIVE FORCES 68
4.3 EUROPE CLINICAL TRIAL MARKET FOR EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET 69
4.4 DISTRIBUTION OF PRODUCTS BY PHASE 76
5 EPIDEMIOLOGY 77
6 MARKET OVERVIEW 80
6.1 DRIVERS 82
6.1.1 GROWING PREVALENCE OF HEPATITIS 82
6.1.2 INCREASE IN HEALTHCARE EXPENDITURE 83
6.1.3 ONGOING RESEARCH AND DEVELOPMENT INITIATIVES 83
6.1.4 ADVANCES IN DIAGNOSTIC TECHNOLOGIES 84
6.2 RESTRAINTS 86
6.2.1 LIMITED AWARENESS OF HEPATITIS DELTA VIRUS (HDV) 86
6.2.2 HIGH COST OF TREATMENT 86
6.3 OPPORTUNITIES 88
6.3.1 RISING INNOVATIVE DRUG DEVELOPMENT 88
6.3.2 INCREASING DEVELOPMENT OF COMBINATION THERAPIES 90
6.3.3 GROWING ADVANCEMENTS IN DIGITAL HEALTH SOLUTIONS 91
6.4 CHALLENGES 92
6.4.1 SIDE EFFECTS OF CURRENT TREATMENTS 92
6.4.2 SLOW REGULATORY APPROVALS 93
7 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE 94
7.1 OVERVIEW 95
7.2 ACUTE HEPATITIS D 98
7.3 CHRONIC HEPATITIS D 98
8 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT 99
8.1 OVERVIEW 100
8.2 SURGERY (LIVER TRANSPLANT) 103
8.3 MEDICATION 103
8.3.1 APPROVED THERAPIES 104
8.3.1.1 PEGYLATED INTERFERON ALPHA 104
8.3.1.2 ENTRY INHIBITOR (BULEVIRTIDE) 104
8.3.2 EMERGING THERAPIES 104
9 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM 105
9.1 OVERVIEW 106
9.2 TABLET 109
9.3 CAPSULE 109
9.4 INJECTABLE 110
10 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE 111
10.1 OVERVIEW 112
10.2 BRANDED 115
10.3 GENERIC 115
11 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION 116
11.1 OVERVIEW 117
11.2 ORAL 120
11.2.1 TABLET 120
11.2.2 CAPSULE 120
11.2.3 OTHERS 120
11.3 PARENTERAL 121
12 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER 122
12.1 OVERVIEW 123
12.2 FEMALE 126
12.3 MALE 126
13 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP 127
13.1 OVERVIEW 128
13.2 ADULTS 131
13.3 GERIATRIC 131
13.4 PEDIATRIC 132
14 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION 133
14.1 OVERVIEW 134
14.2 CONTAMINATED NEEDLES 137
14.3 EXPOSURE TO INFECTED BLOOD 137
14.4 BLOOD AND PLASMA PRODUCT TRANSFUSION 138
14.5 OTHERS 138
15 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER 139
15.1 OVERVIEW 140
15.2 HOSPITALS 143
15.3 SPECIALTY CENTERS 143
15.4 HOME CARE SETTING 144
15.5 RESEARCH INSTITUTES & ACADEMIC CENTERS 144
15.6 AMBULATORY SURGICAL CENTERS 145
15.7 OTHERS 145
16 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL 146
16.1 OVERVIEW 147
16.2 DIRECT TENDER 150
16.3 RETAIL SALES 150
16.3.1 HOSPITAL PHARMACY 151
16.3.2 RETAIL PHARMACY 151
16.3.3 ONLINE PHARMACY 151
16.4 OTHERS 151
17 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION 152
17.1 EUROPE 155
17.1.1 GERMANY 160
17.1.2 FRANCE 164
17.1.3 U.K 168
17.1.4 ITALY 172
17.1.5 SPAIN 176
17.1.6 NETHERLANDS 180
17.1.7 SWITZERLAND 184
17.1.8 RUSSIA 188
17.1.9 BELGIUM 192
17.1.10 TURKEY 196
17.1.11 DENMARK 200
17.1.12 SWEDEN 204
17.1.13 POLAND 208
17.1.14 NORWAY 212
17.1.15 FINLAND 216
17.1.16 REST OF EUROPE 220
18 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: COMPANY LANDSCAPE 221
18.1 COMPANY SHARE ANALYSIS: EUROPE
19 SWOT ANALYSIS 222
20 COMPANY PROFILE 223
20.1 GILEAD SCIENCES, INC. 223
20.1.1 COMPANY SNAPSHOT 223
20.1.2 REVENUE ANALYSIS 224
20.1.3 COMPANY SHARE ANALYSIS 224
20.1.4 PIPELINE PRODUCT 225
20.1.5 RECENT DEVELOPMENTS 225
20.2 GENENTECH, INC. 227
20.2.1 COMPANY SNAPSHOT 227
20.2.2 PRODUCT PORTFOLIO 227
20.2.3 RECENT DEVELOPMENT 227
20.3 ALNYLAM PHARMACEUTICALS, INC. 228
20.3.1 COMPANY SNAPSHOT 228
20.3.2 REVENUE ANALYSIS 228
20.3.3 PIPELINE PRODUCT 229
20.3.4 RECENT DEVELOPMENTS 229
20.4 ASSEMBLY BIOSCIENCES, INC. 230
20.4.1 COMPANY SNAPSHOT 230
20.4.2 REVENUE ANALYSIS 230
20.4.3 PIPELINE PRODUCT 231
20.4.4 RECENT DEVELOPMENTS 231
20.5 EIGER BIOPHARMACEUTICALS 232
20.5.1 COMPANY SNAPSHOT 232
20.5.2 REVENUE ANALYSIS 232
20.5.3 COMPANY SHARE ANALYSIS 233
20.5.4 PRODUCT PORTFOLIO 233
20.5.5 PIPELINE PRODUCT 233
20.5.6 RECENT DEVELOPMENT 234
20.6 GLOBEIMMUNE INC. 235
20.6.1 COMPANY SNAPSHOT 235
20.6.2 PIPELINE PRODUCT 235
20.6.3 RECENT DEVELOPMENT 235
20.7 HUAHUI HEALTH LTD. 236
20.7.1 COMPANY SNAPSHOT 236
20.7.2 PIPELINE PRODUCT 236
20.7.3 RECENT DEVELOPMENT 236
20.8 JOHNSON & JOHNSON SERVICES, INC. 237
20.8.1 COMPANY SNAPSHOT 237
20.8.2 REVENUE ANALYSIS 237
20.8.3 PIPELINE PRODUCT 238
20.8.4 RECENT DEVELOPMENT 238
20.9 PHARMAESSENTIA CORPORATION 239
20.9.1 COMPANY SNAPSHOT 239
20.9.2 REVENUE ANALYSIS 239
20.9.3 PIPELINE PRODUCT 240
20.9.4 RECENT DEVELOPMENT 240
20.10 REPLICOR 241
20.10.1 COMPANY SNAPSHOT 241
20.10.2 PIPELINE PRODUCT 241
20.10.3 RECENT DEVELOPMENTS 242
20.11 VIR BIOTECHNOLOGY, INC. 243
20.11.1 COMPANY SNAPSHOT 243
20.11.2 REVENUE ANALAYSIS 243
20.11.3 PRODUCT PIPELINE 244
20.11.4 RECENT DEVELOPMENTS 244
21 QUESTIONNAIRE 245
22 RELATED REPORTS 249